DIA
Drug Information Association Logo

Consequences of Non-compliance to Osteoporosis Medication Among Osteoporotic Women

Time

Tue, Jun 25 11:45AM
T 33

Title

Consequences of Non-compliance to Osteoporosis Medication Among Osteoporotic Women

Abstract Summary

A retrospective analysis using i3 Invision Datamart (Ingenix, Eden Prairie, MN) from January 1, 2001 to December 31, 2010 (study period) was conducted. Women =55 years old who initiated an OP medication (alendronate, ibandronate, risedronate, zoledronate, raloxifene, calcitonin, teriparitide) during study period and had enrolled in the database for 3 consecutive years: 1 year before the index prescription (baseline), a compliance year (year 1), and a follow-up year (year 2) were included in the study. Subjects were excluded if they had Paget's disease or diagnosis of malignant neoplasm. Non-compliance to OP medication was defined as medication possession ratio (MPR) <0.8 during year 1 (MPR = total number of days’ supply/365 days). Occurrence of OP-related hip, vertebral, and non-vertebral fracture and healthcare resource use and were assessed during year 2. Logistic regression was conducted to assess the association of non-compliance on occurrence of fractures and healthcare resources, while Poisson regression was conducted to assess the association with number of healthcare events.

Poster Presenter

Ankita Modi
PhD,
Director,
Merck & Co., Inc.
United States

© 2015 DIA